Human Genome Epidemiology Literature Finder
Records 1 - 17 (of 17 Records) |
Query Trace: Nausea and UGT1A1[original query] |
---|
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. British journal of cancer 2004 Aug 91 (4): 678-82. Marcuello E, Altés A, Menoyo A, Del Rio E, Gómez-Pardo M, Baiget |
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study. The oncologist 2006 Sep 11 (8): 944-54. de Jong Floris A, Kehrer Diederik F S, Mathijssen Ron H J, Creemers Geert-Jan, de Bruijn Peter, van Schaik Ron H N, Planting André S Th, van der Gaast Ate, Eskens Ferry A L M, Janssen Jos Th P, Ruit Jan B, Verweij Jaap, Sparreboom Alex, de Jonge Maja J |
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006 Mar 106 (5): 1007-16. Massacesi Cristian, Terrazzino Salvatore, Marcucci Fabiana, Rocchi Marco B, Lippe Paolo, Bisonni Renato, Lombardo Marco, Pilone Alberta, Mattioli Rodolfo, Leon Alber |
Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study. Anticancer research 2011 Jan 31 (1): 359-66. Freyer Gilles, Duret Aude, Milano Gerard, Chatelut Etienne, Rebischung Christine, Delord Jean-Pierre, Merrouche Yacine, Lledo Gerard, Etienne Marie-Christine, Falandry Clai |
FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC research notes 2014 7 (1): 260. Bécouarn Yves, Cany Laurent, Pulido Marina, Beyssac Richard, Texereau Patrick, Le Morvan Valérie, Béchade Dominique, Brunet René, Aitouferoukh Sofiane, Lalet Caroline, Mathoulin-Pélissier Simone, Fonck Marianne, Robert Jacqu |
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. The oncologist 2017 Feb . Kim Ji-Won, Lee Keun-Wook, Kim Kyu-Pyo, Lee Ju Hyun, Hong Yong Sang, Kim Jeong-Eun, Kim Sun Young, Park Sook Ryun, Nam Byung-Ho, Cho Sang-Hee, Chung Ik-Joo, Park Young Suk, Oh Ho-Suk, Lee Myung-Ah, Kang Hye Jin, Park Young Iee, Song Eun-Kee, Han Hye Sook, Lee Kyu Taeg, Shin Dong Bok, Kang Jung Hun, Zang Dae Young, Kim Jee Hyun, Kim Tae W |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms. Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan 2017 02 37 (1): 35-42. Deng Bo, Jia Liqun, Tan Huangying, Lou Yanni, Li Xue, Li Yuan, Yu Li |
Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer chemotherapy and pharmacology 2017 10 80 (6): 1239-1247. Yoshino Kiyoshi, Kamiura Shoji, Yokoi Takeshi, Nakae Ruriko, Fujita Masami, Takemura Masahiko, Adachi Kazushige, Wakimoto Akinori, Nishizaki Takamichi, Shiki Yasuhiko, Tsutsui Tateki, Kanda Yuki, Kobayashi Eiji, Hashimoto Kae, Mabuchi Seiji, Ueda Yutaka, Sawada Kenjiro, Tomimatsu Takuji, Kimura Tadas |
Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype-Guided Dosing. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 9 26 (1): 18-24. Joshi Smita S, Catenacci Daniel V T, Karrison Theodore G, Peterson Jaclyn D, Zalupski Mark M, Sehdev Amikar, Wade James, Sadiq Ahad, Picozzi Vincent J, Amico Andrea, Marsh Robert, Kozloff Mark F, Polite Blase N, Kindler Hedy L, Sharma Manish |
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Cancer 2019 Jan . Sharma Manish R, Joshi Smita S, Karrison Theodore G, Allen Kenisha, Suh Grace, Marsh Robert, Kozloff Mark F, Polite Blase N, Catenacci Daniel V T, Kindler Hedy |
Safety and cardiovascular effects of multiple-dose administration of aripiprazole and olanzapine in a randomised clinical trial. Human psychopharmacology 2020 9 36 (1): 1-12. Koller Dora, Almenara Susana, Mejía Gina, Saiz-Rodríguez Miriam, Zubiaur Pablo, Román Manuel, Ochoa Dolores, Wojnicz Aneta, Martín Samuel, Romero-Palacián Daniel, Navares-Gómez Marcos, Abad-Santos Francis |
ABCB1 Genetic Variants as Predictors of Irinotecan-Induced Severe Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. Frontiers in pharmacology 2020 7 11 973. Riera Pau, Artigas-Baleri Alícia, Salazar Juliana, Sebio Ana, Virgili Anna C, Arranz María Jesús, Páez Dav |
Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. Advances in therapy 2020 6 37 (8): 3537-3550. Zubiaur Pablo, Saiz-Rodríguez Miriam, Ochoa Dolores, Navares-Gómez Marcos, Mejía Gina, Román Manuel, Koller Dora, Soria-Chacartegui Paula, Almenara Susana, Abad-Santos Francis |
Gilbert's Syndrome, Bilirubin Level and UGT1A1?28 Genotype in Men of North-West Region of Russia. Journal of clinical and experimental hepatology 2021 12 11 (6): 691-699. Ivanov Andrei, Semenova Ele |
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. The pharmacogenomics journal 2021 Jan . Vivaldi Caterina, Crucitta Stefania, Catanese Silvia, Cucchiara Federico, Arrigoni Elena, Pecora Irene, Rofi Eleonora, Fornaro Lorenzo, Salani Francesca, Massa Valentina, Vasile Enrico, Morganti Riccardo, Danesi Romano, Del Re Marz |
Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer. Genetic testing and molecular biomarkers 2023 5 27 (5): 133-141. Zineb Aoullay, Andrew Smith, Meriem Slaoui, Ihssane El Bouchikhi, Hassan Ghazal, Najib Al Idrissi, Bouchra Meddah, Kara L Lynch, Yahia Cherrah, Alan H B |
A single-center retrospective analysis of the efficacy and safety of a modified regimen of irinotecan plus S-1 (IRIS) with molecular targeting agents as second-line chemotherapy in Japanese patients with recurrent or nonresectable colorectal cancer. Journal of gastrointestinal oncology 2023 5 14 (2): 663-675. Shigeo Higami, Masaya Mukai, Daiki Yokoyama, Syuji Uda, Rin Abe, Nana Mamuro, Kyoko Kishima, Sayuri Hasegawa, Takayuki Tajima, Eiji Nomura, Hiroyasu Makuuc |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: